Journal ArticleDOI
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi Sciacca,Paul Clopton,E. Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro +12 more
Reads0
Chats0
TLDR
Administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.About:
This article is published in Gastroenterology.The article was published on 2013-09-01. It has received 794 citations till now. The article focuses on the topics: Insulin resistance & Nonalcoholic fatty liver disease.read more
Citations
More filters
Journal ArticleDOI
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Giulio Marchesini,Christopher P. Day,Jean-François Dufour,Ali Canbay,Valerio Nobili,Vlad Ratziu,Herbert Tilg,Michael Roden,Amalia Gastaldelli,Hannele Yki-Järvinen,Fritz Schick,Roberto Vettor,Gema Frühbeck,Lisbeth Mathus-Vliegen +13 more
TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.
Journal ArticleDOI
Mechanisms of NAFLD development and therapeutic strategies
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.
TL;DR: Host metabolism can be affected through microbial modifications of bile acids, which lead to altered signaling via bile acid receptors, but also by altered microbiota composition.
Journal ArticleDOI
From NASH to HCC: current concepts and future challenges.
Quentin M. Anstee,Quentin M. Anstee,Helen L. Reeves,Helen L. Reeves,Elena Kotsiliti,Olivier Govaere,Mathias Heikenwalder +6 more
TL;DR: This Review discusses NAFLD-associated HCC, including its epidemiology, key features that promote hepatocarcinogenesis and the management of HCC in patients with obesity and associated metabolic comorbidities, and the challenges and future directions of research.
References
More filters
Journal ArticleDOI
Epidemic trends of obesity with impact on metabolism and digestive diseases.
TL;DR: Keeper understanding of nonmalignant and malignant digestive diseases dependencies on obesity will yield a deeper understanding which is necessary to improve prevention and treatment concepts of this epidemic.
Journal ArticleDOI
Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans
Hanns-Ulrich Marschall,Martin Wagner,Gernot Zollner,Peter Fickert,Dagmar Silbert,Ulf Gustafsson,Staffan Sahlin,Michael Trauner +7 more
TL;DR: Combination treatment with both RIFA and UDCA preserves the previously observed beneficial effects of single treatment with RIFA, including stimulation of bile acid synthesis, which in humans is not mediated by FGF19.
Related Papers (5)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more